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Modern oncology witnesses an increasing number of new effective anticancer 
drugs targeting specific oncogenic pathways. Despite these advances, real-world 
experience with targeted single agents is disappointing since drug resistance usually 
occurs after a short time. This is particularly true for patients with refractory or 
relapsed T-cell lymphoma (TCL) who so far could not benefit from novel agents and 
demonstrate a short survival time of only 3 months. The novel genetic information 
gained from genome-wide high-throughput techniques has greatly improved our 
understanding of TCL. However, if precision medicine strategies are based solely on 
genetics, it runs into two major challenges: (1) the heterogeneity within the cancer 
of an individual patient and (2) the incomplete understanding of the degree of con-
tribution of a specific mutation to a tumor phenotype. Next-generation functional 
drug screening (ngFDS) aims to address these problems. Studies that proof the 
clinical utility of ngFDS are currently limited. The following chapter aims to discuss 
recent advances of ngFDS and to line out its potential for TCL patients.
Keywords: T-cell lymphoma, precision medicine, genomics, transcriptomics,  
next-generation functional screening
1. Introduction
TCL is a heterogeneous group of rare lymphoid malignancies generally with 
dismal outcome [1, 2]. With current treatment options, a majority of patients 
do not achieve remission or experience relapse after completion of therapy 
[3–6]. Patients with newly diagnosed TCL are most commonly treated with 
anthracycline-based (CHOP-like) chemotherapy regimens, often followed by 
consolidation with high-dose chemotherapy and stem cell transplantation in 
eligible patients [1]. Patients with relapsed TCL have a dismal prognosis with a 
median overall survival of only 3 months [2]. Unfortunately, mechanisms of drug 
resistance in TCL leading to progression and relapse remain elusive, and predic-
tive biomarkers do not exist, precluding clinical progress. Three major limita-
tions have thus far hampered a systematic and causative understanding of drug 
resistance in TCL: (I) adherence to genetic studies and barriers in translating this 
genomic information into direct clinical benefit for patients, (II) as for functional 
analysis, a general adherence to cell lines that is prone to clonal artifacts and 
that not faithfully recapitulates relevant physiology, and (III) lack of consider-
able biobanks of viably frozen cells from fresh dissociated lymphomas. All three 
points are discussed in detail below.
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2. Precision medicine concepts
2.1 Advances and shortcomings of genetic studies
Predicting clinical treatment outcome from detailed characterization of patient 
material is one of the key challenges of modern oncology. The most so-called 
precision medicine approaches either rely on correlation of clinical outcome with 
molecular profiles such as genetic mutations [7] or attempt to reproduce the disease 
in an ex vivo model system and extrapolate from measured drug response to the 
patient outcome [8, 9]. Genetic approaches are state of the art for most diseases 
and have also been successful in some indications (e.g., targeting BCR-ABL with 
imatinib in chronic myeloid leukemia (CML)). TCLs, however, as most cancers, 
categorically differ from the rare monogenetic disease model and are driven by 
microevolutionary processes leading to broad genetic heterogeneity [10] and mak-
ing a purely correlational logic extremely challenging [11].
Recent sequencing studies in TCL confirmed a set of genetic alterations in specific 
subtypes, including recurrent mutations in the epigenetic modifiers TET2, IDH2, 
and DNMT3A and the small GTPase RhoA in angioimmunoblastic T-cell lymphoma 
(AITL) [12–15], while JAK/STAT pathway alterations through mutations at various 
levels seem to be present across all TCL subtypes, particularly in anaplastic large 
cell lymphoma (ALCL) [16]. For the most common subtypes of TCL, including 
peripheral T-cell lymphoma not otherwise specified (PTCL-NOS), AITL, and ALCL, 
genetic data are largely based on targeted DNA sequencing approaches focusing on 
mutations in pre-selected panels of genes, while unbiased sequencing approaches like 
whole exome sequencing are only available in small cohorts. Previous studies in ALK- 
ALCL utilizing immunohistochemistry and fluorescence in situ hybridization identi-
fied for ~38% of the patients with ALK- ALCL DUSP22- and TP63-rearrangements to 
be associated with good prognosis as for DUSP22- or with exceptional dismal progno-
sis as for TP63- rearrangements when receiving CHOP-like regimens [17].
Despite the significant amount of recurrent mutations in genes involved in DNA 
methylation like DNMT3A, TET2, or IDH2, no genome-wide epigenetic profiling 
has been reported in a sufficient amount of clinically well-annotated samples  
[12, 13, 18]. Therefore, we currently only can assume that broad epigenetic changes 
are frequent in TCL. In contrast to B-cell lymphoma, relatively strong responses to 
epigenetic modifying agents, such as HDAC inhibitors and methylation modifiers, 
are clinically evident [19–21].
Thus, there is evidence that in TCL the epigenome is of particular importance; 
however, systematic studies on epigenetic profiling in TCL are lacking and so are 
direct connections of genetic mutations in epigenetic modifiers and clinical responses 
to epigenetic drugs. A comprehensive characterization of genetic and epigenetic 
alterations and clinical response to specific drugs is highly warranted for TCL.
2.2 Advances and shortcomings of functional studies
Despite significant success to identify genomic alterations that might establish 
and drive hematologic malignancies, genetic studies face problems in translating 
genomic information into drug-able targets to directly benefit the patients. Results 
of personal medical efforts in cancer patients so far are sometimes promising but 
with the majority rather appearing disappointing [22–26]. In a landmark study that 
used each patient as their own control, Von Hoff et al. reported that 27% of patients 
with recurrent metastatic cancer of any kind had a 30% longer progression-free 
survival (PFS) with treatment selected on the basis of genetic profiling than they 
did with their previous treatment [25].
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The first randomized trial of genomic-based precision medicine, the SHIVA 
study, did not use patients as their own control but investigated the effect of genetic 
marker-based targeted treatment comparing with treatment at physician’s choice 
in heavily pretreated patients with cancer. The SHIVA study failed to demonstrate 
a benefit for patients treated with genetic precision treatment [26]. We need to 
consider that our knowledge of how cancer genotype relates to its phenotype and 
of the complexity of the dynamic microevolutionary procedures that occur in an 
individual cancer is very limited [10].
Therefore, dynamic approaches that measure drug responses in cancer cells 
derived from patient biopsies promise to complement the static molecular measure-
ments. Functional approaches could contribute important information to improve 
the selection of the right drug for the right patient at the right time. For instance, 
ex vivo chemosensitivity tests have been performed in samples of patients suffering 
chronic or acute leukemia [8, 27–30] and also in gut stem cell-derived organoids  
[31, 32], in breast cancer cell lines [33], and in xenografted mice [34, 35]. All 
these pioneering functional studies have not been integrated into clinical routine, 
but they provided proof of concept for ex vivo responses that may match clinical 
response. However, due to the extensive time of the assays used, the clinical benefits 
were limited [36–38]. First proof of concept data was obtained with functional 
screens detecting drug activity in cell cultures with luminescent assays that pre-
dicted activity and resistance to drugs in patients [9] and leading to initiation of a 
clinical trial for targeted therapy of relapsed acute myeloid leukemia [39].
In two recent reports, luminescent assay-based drug profiling has also been 
performed in a T-cell neoplasm and in T-cell prolymphocytic leukemia (T-PLL)  
[40, 41]. T-PLL is a rare, clinically heterogenous neoplasm, which is treated with 
alemtuzumab-based induction in patients with symptoms, followed by consolida-
tive stem cell transplantation [42]. There are no randomized controlled trials that 
inform the management of T-PLL; thus it is an area of clear unmet need. Boidol 
et al. used single-cell suspensions from fresh bone marrow, peripheral blood, or 
lymph node samples from 86 patients and exposed cells to 106 different compounds 
to perform functional drug screening after 72 hours [41]. Cancer cell-specific 
responses were calculated from individual dose-response curves, and tissue micro-
arrays were generated for comparative protein expression profiling (Figure 1).
BCL-2 inhibitor venetoclax exhibited the strongest differential response for 
T-PLL (Figure 2). Ex vivo responses to venetoclax significantly correlated with 
BCL-2 protein expression scores but not with scores for BCL-2 gene family mem-
bers BCL-XL and MCL-1. BCL-XL and MCL-1 expression scores demonstrated a 
significant correlation, while only MCL-1 appears to be inversely correlated with 
BCL-2 expression. T-PLL samples were among the entities with the highest BCL-2 
scores, showing the most dramatic response to BCL-2 inhibition via venetoclax. 
Importantly, the second ex vivo dug screening report on T-PLL also found con-
sistent activities of BCL-2 inhibition in T-PLL, thus confirming these results in an 
independent cohort [40] (Figure 2). It also demonstrates the reliability and repro-
ducibility of functional assays.
It is noteworthy that luminescent assay-based functional assays can recapitu-
late differential responses to venetoclax of specific disease entities experienced 
in the clinic. High-resolution dose-response curves of venetoclax clearly distin-
guished CLL, AML, and T-PLL samples (Figure 3). As expected from clinical 
data, CLL samples demonstrated pronounced effects at already very discrete 
doses (50% inhibitory concentration [IC50], around 5 nM). In contrast AML 
samples responded at high concentrations (median IC50: 10 μM). Response 





Workflow: After sampling, single cell suspensions are used for high-throughput drug-screening. Formaldehyde 
conserved samples are processed for tissue microarrays for comparative protein expression profiling.
Figure 2. 
Cancer cell-specific responses were calculated from individual dose-response curves in two independent 
publications. In both, drug-profiling revealed that BCL-2 inhibitor venetoclax exhibited a significant 
differential response for T-PLL.
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Trying to elucidate the mechanisms, we investigated the protein expression of 
other BCL-2 family members. Interestingly venetoclax treatment induced BCL-2 
and BCL-XL protein expression in the two patients, since MCL-1 levels did not 
changed. Therefore BCL-XL upregulation could be a potential mechanism of 
Figure 3. 
High-resolution dose-response curves of venetoclax in CLL, AML, and T-PLL samples.
Figure 4. 
Venetoclax treatment induced BCL-2 and BCL-XL protein expression.
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venetoclax resistance, and the additional use of drugs targeting BCL-XL or sup-
pressing BCL-XL could be mechanistically synergistic (Figure 4).
Therefore, studies testing venetoclax with appropriate combination partners 
in T-PLL are warranted. Combination therapies are essential to overcome the 
resistance mechanisms that limit the long-term efficacy of conventional cytotoxic 
chemotherapies or targeted agents inhibiting single pathways. It is important to 
establish a workflow to systematically test multiple drug combinations and applied 
it to successfully identify synergistic combinations [43]. The main challenges 
to systematic large-scale drug-drug combination testing are that the number of 
two-drug combination remains in tens of thousands, thus limiting the numbers of 
combinations to be tested in primary patient material. To overcome this burden, 
the community continues to develop innovative computational approaches for 
preselecting sets of putative synergistic drugs involving network analysis, dynamic 
modeling, and high-content machine learning. However, based mainly on genetic 
data, only approx. 40% in silico predicted drug synergies are confirmed by ex vivo 
combination testing as demonstrated at the example of T-cell prolymphocytic leu-
kemia (T-PLL) [44]. A reason for the rather low functional confirmation rate could 
be the low correlation between high-throughput ex vivo drug testing and mutation 
profiling [40]. It is therefore tempting to propose a smart way to preselect combina-
tion partners that are then analyzed in vitro.
2.3 Advances of single-cell functional studies
Luminescent assay-based functional assays have the big plus of high-through-
put because full automation is more easily established. However, these assays 
cannot provide data at the single-cell level and thus no data on individual cell 
based functional information. Especially if the aim is to address the heterogeneity 
within one individual patient, i.e., to discriminate malignant and normal cells or 
to use complex co-culture systems, investigators could be interested in automated 
microscopic imaging technology. Minimally invasive protocols could provide 
drug-response information in co-culture systems. This could maintain leukemia 
and multiple myeloma cells for a longer cultivating time and enhance the screen-
ing capabilities of patient samples [45–47]. Snijder and colleagues investigated 
the clinical impact of a newly developed single-cell image analysis technology 
platform that operates using a combination of multi-parametric immunofluores-
cence and high-throughput automated microscopy [48]. In contrast to functional 
methods used previously, this next-generation functional drug screening (ngFDS) 
technique allows a fast tumor cell -specific quantification of biological parameters 
of millions of adherent and non-adherent individual cells with high sample effi-
ciency, minimal sample manipulation, extensive automation, and fast turnaround 
times [49] (Figure 5).
The authors demonstrated that multi-parametric, image-based, immunopheno-
typic cytometry could reliably distinguish malignant cells from normal bystander 
cells in a high-content screening context. They showed how this approach can 
detect phenotypes across several cellular compartments, quantifying, for example, 
T-cell engagement by the bispecific, CD19-directed, T-cell engager blinatumomab 
in patient samples. They applied the method to patients with aggressive hemato-
logic malignancies failing at least two lines of therapy and without further standard 
treatment options. These patients will usually receive either best available therapy 
or best supportive care or will be enrolled in clinical trials. Upon relapse, blood, 
bone marrow, pleural effusions, or excised lymph node biopsies were collected 
depending on the disease manifestation. The primary endpoints were to evaluate 
the feasibility of integrating ngFDS into the clinic and to assess clinical response 
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in patients who received a treatment according to ngFDS results as an individual 
healing attempt [49] (Figure 6).
This prospective single-center pilot study demonstrates that it is possible to 
integrate automated microscopy-based next-generation functional drug screening 
(ngFDS) for patients with aggressive hematologic malignancies into the clinical 
routine. Importantly, the ngFDS results suggested treatment regimens that lead to 
an improved ORR and longer PFS for patients than the last treatment regimen the 
patients had just experienced progression on (Figure 7). These results demonstrate 
that we are already in possession of a wide array of working chemotherapeutics and 
Figure 5. 
Next-generation functional drug screening (ngFDS) technique allows a fast tumor cell-specific quantification 
of biological parameters of millions of adherent and non-adherent individual cells.
Figure 6. 
Blood, bone marrow, pleural effusions, or excised lymph node biopsies were collected depending on the disease 
manifestation. The primary endpoints were to evaluate the feasibility of integrating ngFDS into the clinic and 
to assess clinical response.
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targeted inhibitors that in principle are capable of breaking drug resistance even in 
multi-refractory cancers, given that we identify the right drugs for each individual 
patient, at the right time during their treatment.
The study name is EXALT for extended analysis for leukemia/lymphoma 
treatment. It is a prospective non-randomized study with each patient functioning 
as their own control, thus allowing to determine the overall effect across heteroge-
neous disease entities and different therapies. The nonexistence of randomization 
could harbor a bias. In future studies testing ngFDS-guided therapies, randomiza-
tion and physician choice are warranted.
Image-based quantification of drug effects with single-cell resolution in patient 
biopsies, as introduced here, represents a robust and clinically useful platform to 
assign powerful individualized therapeutic regimens. The strength of the approach 
resides in the statistical power derived from monitoring with computer-aided 
precision millions of individual functional events, i.e., single-cell drug responses, 
combined with the ability to discriminate cell types, allowing to score specific 
rather than general and averaged cytotoxic effects. The approach may be valuable 
for the personalized identification of clinically effective therapies for many other 
hematological malignancies, especially for rare diseases, like TCL. The selection 
of personalized therapy by ngFDS benefits from the ability to measure hundreds 
to thousands of drug exposures using small patient samples, where each ex vivo 
treatment includes healthy-cell-controls from the same patient sample. This allows 
for direct estimation of the therapeutic window, while the minimal ex vivo culturing 
of cells and compatibility with clinical diagnostic markers ensure fast and relevant 
feedback. Further, the platform can take advantage of the use of liquid biopsies 
where small target cells can be detected. These integrated drug response profiles, 
or “chemotypes,” of individual people are the culmination of the interplay between 
a number of molecular parameters of the responding cells, including not only the 
genetic, proteomic, and metabolic state of the cells but also the direct and indirect 
molecular interactions with other cells [48], recapitulating relevant physiological 
complexity. Such chemotypes may offer functional insight into the underlying 
health status of an individual, with potentially wide-ranging implications also in 
preventative and participatory medicine.
As shown here, ngFDS can provide clinically useful guidance in the absence 
of genetic information. However, the full potential of the approach will certainly 
be realized only through the synergy with genomic and other molecular patient 
profiling. This could lead to highly accurate personalized treatments, coupled with 
companion diagnostics, as well as powerful route to mechanistic elucidation of 
gene-to-phenotype relationships.
Figure 7. 
ngFDS results suggested treatment regimens that lead to an improved ORR and longer PFS for patients than the 
last treatment regimen the patients had just experienced progression on.
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2.4 Outlook for precision medicine in TCL
Collectively, the combination of advanced functional strategies, chemical genet-
ics, and phenotypic screening approaches to holistically chart and chemically probe 
mechanisms of drug failure opens fundamental new treatment opportunities for 
TCL patients. Phenotypic single-cell drug screening is a highly innovative approach 
that helps to identify sensitive drugs and proved to be effective in late-stage hema-
tological malignancies [49]. The next step to achieve the real treatment goal of a 
“long-term remission” is to identify a systematic way to identify mechanistically 
grounded effective drug-drug combinations. Clinically fully annotated viable 
sample sets consisting of sufficient TCL samples will provide the basis to probe 
with the help of network analysis, dynamic modeling, and high-content machine 
learning a useful algorithm for individual combination treatment to tackle drug 
resistance up-front.
Novelty emerges from the innovative intersection of cutting edge technologies, 
such as an innovative drug screening pipeline at cellular resolution, the use of novel 
immune competent xenograft mouse models that recapitulate human immune 
response, and single-cell RNAseq applied in primary TCL cells upon multiple drug 
perturbations. Foremost, it will be important to probe these data sets with cutting 
edge bioinformatics and network medicine pipelines.
ngFDS will give hemato-oncologists a new tool to identify the most promising 
treatment combinations to help overcome resistance in otherwise refractory TCLs 
on a patient-to-patient basis. The success of ngFDS, added a new layer to how 
doctors can base treatment decisions, since it significantly improved the patients’ 
outcome [49]. A rational guidance to pick the most appropriate combination 
partner promises to achieve long-term remissions.
I further expect that the established pipelines of ex vivo testing identified drug 
combinations will outline and instruct prospective clinical trials as has recently 
shown [41, 45] (approval and funding of a clinical study starting Q4 2018: vene-
toclax + ibrutinib in T-PLL (VIT-study;) Ph2 Study M18–803 (AbbVie) = the first 
global clinical trial for T-PLL).
Finally, ngFDS challenges the concepts of future clinical trial design. It requires 
a study design that provides the highest possible flexibility for experimental treat-
ment to allow data-guided combination of targeted agents with antibody-based 
therapies for TCL. Larger prospective studies should focus on specific disease 
entities and randomize between arms of different treatment selection procedures to 
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